D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 51 Citations 9,004 105 World Ranking 2605 National Ranking 97

Overview

What is she best known for?

The fields of study she is best known for:

  • Gene
  • Cancer
  • Immune system

Andrea Anichini spends much of her time researching Immunology, Cancer research, Antigen, Cytotoxic T cell and Melanoma. Andrea Anichini focuses mostly in the field of Cancer research, narrowing it down to matters related to Mutation and, in some cases, Carcinogenesis, Oncogene and Receptor. In Antigen, Andrea Anichini works on issues like Immunotherapy, which are connected to Immunogenicity, Monoclonal, Phases of clinical research and Cisplatin.

Her Cytotoxic T cell research is multidisciplinary, incorporating elements of Melanocyte differentiation and CD3. The various areas that Andrea Anichini examines in her Melanoma study include Monoclonal antibody and Pathology. Her research in CTL* focuses on subjects like Molecular biology, which are connected to HLA-A2 Antigen and Clone.

Her most cited work include:

  • Role of Macrophage Targeting in the Antitumor Activity of Trabectedin (482 citations)
  • Interleukin-12: biological properties and clinical application. (442 citations)
  • Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? (376 citations)

What are the main themes of her work throughout her whole career to date?

Her primary scientific interests are in Cancer research, Immunology, Melanoma, Cytotoxic T cell and Antigen. Her Cancer research research is multidisciplinary, incorporating perspectives in Apoptosis, Programmed cell death, Receptor tyrosine kinase and Oncogene. T cell, CD8, Immune system, T-cell receptor and Immunotherapy are among the areas of Immunology where the researcher is concentrating her efforts.

Her study in Immune system is interdisciplinary in nature, drawing from both Immunohistochemistry, Cancer and Internal medicine. Her studies examine the connections between Melanoma and genetics, as well as such issues in Integrin, with regards to Cell biology. The concepts of her Cytotoxic T cell study are interwoven with issues in Molecular biology, T lymphocyte and CD3.

She most often published in these fields:

  • Cancer research (40.43%)
  • Immunology (39.36%)
  • Melanoma (36.70%)

What were the highlights of her more recent work (between 2017-2021)?

  • Cancer research (40.43%)
  • Pembrolizumab (4.26%)
  • Urology (4.26%)

In recent papers she was focusing on the following fields of study:

Her scientific interests lie mostly in Cancer research, Pembrolizumab, Urology, Internal medicine and Immunotherapy. Andrea Anichini is studying Melanoma, which is a component of Cancer research. She works mostly in the field of Pembrolizumab, limiting it down to topics relating to Cystectomy and, in certain cases, Phases of clinical research and Cisplatin, as a part of the same area of interest.

Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology. Her Immunotherapy study which covers Tumor microenvironment that intersects with Gene regulatory network, Computational biology, Gene and Gene signature. Her Antigen research includes elements of Cytotoxic T cell and Monoclonal antibody.

Between 2017 and 2021, her most popular works were:

  • Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study (208 citations)
  • Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade (157 citations)
  • The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy (23 citations)

In her most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Immune system

Her primary areas of study are Cancer research, Melanoma, Immunotherapy, Immunohistochemistry and Immune system. Andrea Anichini combines subjects such as Semaphorin, Cell migration, Lung cancer, Antibody and Gene silencing with her study of Cancer research. Her Antibody research incorporates elements of Cancer cell, Cytotoxic T cell, CD3 and Antigen.

Her Melanoma study combines topics from a wide range of disciplines, such as Apoptosis, Transcription factor, Metastasis and Blot. Her studies deal with areas such as Cystectomy, Carcinoma and Urology as well as Immunotherapy. Her Immune system research includes themes of Cancer therapy, Disease and Intensive care medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Giovanni Germano;Roberta Frapolli;Cristina Belgiovine;Achille Anselmo.
Cancer Cell (2013)

648 Citations

Interleukin-12: biological properties and clinical application.

Michele Del Vecchio;Emilio Bajetta;Stefania Canova;Michael T. Lotze.
Clinical Cancer Research (2007)

622 Citations

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Giorgio Parmiani;Chiara Castelli;Piero Dalerba;Roberta Mortarini.
Journal of the National Cancer Institute (2002)

529 Citations

Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction

Licia Rivoltini;Matteo Carrabba;Veronica Huber;Chiara Castelli.
Immunological Reviews (2002)

335 Citations

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

Tadepally Lakshmikanth;Shannon Burke;Talib Hassan Ali;Silvia Kimpfler.
Journal of Clinical Investigation (2009)

317 Citations

Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

S. Siena;M. Di Nicola;M. Bregni;R. Mortarini.
Experimental Hematology (1995)

290 Citations

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions

A Anichini;A Molla;R Mortarini;G Tragni.
Journal of Experimental Medicine (1999)

265 Citations

Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients

Andrea Anichini;Cristina Maccalli;Roberta Mortarini;Stefania Salvi.
Journal of Experimental Medicine (1993)

260 Citations

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study

Andrea Necchi;Andrea Anichini;Daniele Raggi;Alberto Briganti.
Journal of Clinical Oncology (2018)

258 Citations

BRAF alterations are associated with complex mutational profiles in malignant melanoma

Maria Daniotti;Maria Oggionni;Tiziana Ranzani;Viviana Vallacchi.
Oncogene (2004)

220 Citations

Best Scientists Citing Andrea Anichini

Giorgio Parmiani

Giorgio Parmiani

University of Siena

Publications: 84

Licia Rivoltini

Licia Rivoltini

Fondazione IRCCS Istituto Nazionale dei Tumori

Publications: 62

Soldano Ferrone

Soldano Ferrone

Harvard University

Publications: 48

Thierry Boon

Thierry Boon

Ludwig Cancer Research

Publications: 44

Francesco M. Marincola

Francesco M. Marincola

National Institutes of Health

Publications: 43

Alberto Mantovani

Alberto Mantovani

Humanitas University

Publications: 40

Mario P. Colombo

Mario P. Colombo

University of Milan

Publications: 38

Chiara Castelli

Chiara Castelli

University of Milan

Publications: 37

Pierre Coulie

Pierre Coulie

Université Catholique de Louvain

Publications: 35

Jürgen C. Becker

Jürgen C. Becker

University of Duisburg-Essen

Publications: 32

Steven A. Rosenberg

Steven A. Rosenberg

National Institutes of Health

Publications: 32

Mark J. Smyth

Mark J. Smyth

QIMR Berghofer Medical Research Institute

Publications: 31

Maurizio D'Incalci

Maurizio D'Incalci

Mario Negri Institute for Pharmacological Research

Publications: 29

Theresa L. Whiteside

Theresa L. Whiteside

University of Pittsburgh

Publications: 28

Thomas F. Gajewski

Thomas F. Gajewski

University of Chicago

Publications: 28

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.